Tandutinib in Treating Patients With Progressive Prostate Cancer and Bone Metastases

NCT00390468 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

18

Enrollment

NIH

Sponsor class

Conditions

Metastatic Cancer
Pain
Prostate Cancer

Interventions

DRUG: Tandutinib

Sponsor

National Cancer Institute (NCI)